宣泰医药推出2025年限制性股票激励计划，彰显未来成长信心

Core Viewpoint - The company announced a restricted stock incentive plan aimed at enhancing governance structure and motivating key employees to support long-term development and shareholder returns [1][2][3] Group 1: Incentive Plan Details - The incentive plan involves granting up to 6.23 million shares, representing 1.37% of the total share capital, with an initial grant of 4.99 million shares (80.06% of the total grant) [1] - The plan targets senior management, core technical personnel, middle management, and key employees to create a shared interest among shareholders, the company, and employees [1][3] Group 2: Performance Assessment Criteria - The performance assessment for the restricted stock includes metrics such as return on equity, revenue growth, R&D expenditure, and the number of approved drugs, with specific growth targets set for 2026-2028 [2] - Revenue growth targets are set at no less than 30%, 59%, and 80% for the respective years, with all growth rates required to exceed industry averages [2] Group 3: Product Development and Market Expansion - The company has developed a product matrix covering various therapeutic areas, including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, kidney, and pain management [2] - Recent approvals from the FDA include the formal approval of tofacitinib citrate sustained-release tablets and temporary approval for other products, indicating a growing product pipeline [2] - In the domestic market, the company has received approvals for new specifications and has successfully participated in national drug procurement, enhancing its market presence [3]